Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-01-04
2011-01-04
Chung, Susannah (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S272400, C548S152000, C548S263200
Reexamination Certificate
active
07863299
ABSTRACT:
The present invention relates to novel compounds of formula (IC) or a salt thereof:wherein:p is an integer ranging from 0 to 4;R1is independently selected from a group consisting of: halogen, hydroxy, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, C1-4alkanoyl or SF5; or corresponds to a group R5;m1, m2, m3, and m4are 0;m5, m6and m7are each independently 0, 1 or 2 wherein the sum of m5, m6and m7is 1 or 2;R6is C1-6alkyl;R7is halogen, C1-6alkyl or haloC1-6alkyl;R2is hydrogen or C1-4alkyl;n is 2 or 3;X is S or —CH2—;R3is C1-4alkyl;R4is hydrogen, or a phenyl group, a heterocyclyl group, a 5- or 6-membered heteroaromatic group, or a 8- to 11-membered bicyclic group, any of which groups is optionally substituted by 1, 2, 3 or 4 substituents selected from the group consisting of: halogen, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy and C1-4alkanoyl;R5is isoxazolyl, —CH2—N-pyrrolyl, 1,1-dioxido-2-isothiazolidinyl, thienyl, thiazolyl, pyridyl or 2-pyrrolidinonyl, wherein each group is optionally substituted by one or two substituents selected from: halogen, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy and C1-4alkanoyl;with the proviso that when m5=m6=1, R7is not chlorine;processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as modulators of dopamine D3receptors, e.g. to treat substance related disorders, as antipsychotic agents, premature ejaculation or cognition impairment.
REFERENCES:
patent: 6204284 (2001-03-01), Beer et al.
patent: 2007/0142438 (2007-06-01), Arista et al.
patent: 2007/0249642 (2007-10-01), Bertani et al.
patent: 2008/0058398 (2008-03-01), Anderton et al.
patent: 2008/0167357 (2008-07-01), Hamprecht et al.
patent: 2008/0176917 (2008-07-01), Andreotti et al.
patent: 2008/0227837 (2008-09-01), Arista et al.
patent: 2008/0242715 (2008-10-01), Capelli et al.
patent: 2009/0030062 (2009-01-01), Gentile et al.
patent: 2009/0036461 (2009-02-01), Hamprecht et al.
patent: 2009/0124629 (2009-05-01), Bonanomi et al.
patent: 2009/0221593 (2009-09-01), Bonanomi et al.
patent: 2009/0221618 (2009-09-01), Arista et al.
patent: WO02/040471 (2002-05-01), None
patent: WO 2005/080382 (2005-01-01), None
patent: WO2005/080382 (2005-09-01), None
patent: WO2006/108700 (2006-10-01), None
patent: WO2006/108701 (2006-10-01), None
Patini et al, Chem. Rev., 1996, 96(8), pp. 3147-3176, esp. p. 3150.
U.S. Appl. No. 11/917,352, filed Jun. 13, 2006, Arista, et al.
U.S. Appl. No. 12/295,024, filed Mar. 30, 2007, Bertani, et al.
U.S. Appl. No. 12/295,304, filed Mar. 30, 2007, Bertani, et al.
Capelli Anna Maria
Fazzolari Elettra
Micheli Fabrizio
Tedesco Giovanna
Terreni Silvia
Chung Susannah
Gimmi Edward R.
Glaxo Group Limited
Kanagy James M.
Kinzig Charles M.
LandOfFree
Triazolyl derivatives of azabicyclo [3.1.0] hexane as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Triazolyl derivatives of azabicyclo [3.1.0] hexane as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Triazolyl derivatives of azabicyclo [3.1.0] hexane as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2674900